Leonard R. Duncan

发表

In Vitro Activity and Potency of the Novel Oxazolidinone Contezolid (MRX-I) Tested against Gram-Positive Clinical Isolates from the United States and Europe

C. Carvalhaes, H. Sader, L. Duncan, 2020, Antimicrobial Agents and Chemotherapy.

Ceftobiprole Activity against Bacteria from Skin and Skin Structure Infections in the United States from 2016 through 2018

M. Pfaller, K. Hamed, R. Mendes, 2020, Antimicrobial Agents and Chemotherapy.

Evaluating LC-MS/MS To Measure Accumulation of Compounds within Bacteria.

A. Erwin, Tiansheng Wang, Zhengqi Ye, 2018, ACS infectious diseases.

Regional Analysis of Telavancin and Comparator Antimicrobial Activity against Multidrug-Resistant Staphylococcus aureus Collected in the United States from 2014 through 2016.

R. Mendes, R. Flamm, L. Duncan, 2020, Journal of global antimicrobial resistance.

Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015–16

M. Pfaller, H. Sader, R. Mendes, 2018, The Journal of antimicrobial chemotherapy.

Screen for New Antimicrobial Natural Products from the NCI Program for Natural Product Discovery Prefractionated Extract Library

Jason R. Evans, T. Grkovic, S. Arends, 2023, ACS infectious diseases.

In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii

P. Savoia, S. Hawser, L. Ferrari, 2022, Antibiotics.

Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015-2016.

M. Castanheira, H. Sader, R. Flamm, 2018, Diagnostic microbiology and infectious disease.

A Novel Indole Compound That Inhibits Pseudomonas aeruginosa Growth by Targeting MreB Is a Substrate for MexAB-OprM

G. Robertson, K. Mdluli, Timothy B Doyle, 2007, Journal of bacteriology.

In vitro activity of telavancin against Staphylococcus aureus causing pneumonia or skin and skin structure infections with concomitant bloodstream infections in United States hospitals (2012-2016).

H. Sader, R. Mendes, R. Flamm, 2019, Diagnostic microbiology and infectious disease.

Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens

R. Ebright, Jing Chen, G. Robertson, 2022, Journal of medicinal chemistry.

In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci

Qun Du, T. Morris, D. Yan, 2008, Antimicrobial Agents and Chemotherapy.

Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).

M. Pfaller, K. Hamed, D. Shortridge, 2019, Diagnostic microbiology and infectious disease.

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19).

C. Carvalhaes, H. Sader, R. Mendes, 2022, The Journal of antimicrobial chemotherapy.

Optimization of TopoIV Potency, ADMET Properties, and hERG Inhibition of 5-Amino-1,3-dioxane-Linked Novel Bacterial Topoisomerase Inhibitors: Identification of a Lead with In Vivo Efficacy against MRSA.

Mark J. Mitton-Fry, S. Lindert, C. McElroy, 2021, Journal of medicinal chemistry.

Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).

M. Castanheira, C. Carvalhaes, H. Sader, 2023, Diagnostic microbiology and infectious disease.